Opinion
Video
Treatment Strategies for Patients with NMIBC: Importance of Risk Stratification
Author(s):
A panelist discusses how Non-muscle Invasive Bladder Cancer (NMIBC) treatment varies by risk stratification (low, intermediate, and high-risk), with BCG immunotherapy being standard for high-risk patients, while newer options like pembrolizumab and gene therapies are emerging for BCG-unresponsive cases, and treatment decisions between intravesical versus systemic therapy depend on risk level and previous treatment response.
Video Player is loading.
- Please share where the field of Non-muscle Invasive Bladder Cancer (NMIBC) is right now. Consider the following topics, which will be discussed in depth later on:
- Patient risk stratification
- Approved agents
- Investigational agents
- Please provide a brief overview of risk stratification for patients with NMIBC and treatment strategy for each group.
- What are the FDA-approved agents for treating patients with NMIBC, and what treatment options are available for BCG-naïve and BCG-unresponsive patients?
- How do intravesical therapies compare to intravenous therapies in this context?
Related Videos
Abiraterone Acetate: Generic and Branded Options
A 69-Year-Old Man With Metastatic Hormone Sensitive Prostate Cancer
From Papillary to CIS: Tailoring NMIBC Treatment
Assessing Risk in NMIBC: A Foundation for Therapy
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
BPH Treatment and Impact on Sexual Health
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Related Content
